A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Exclusion Criteria

• •Has primary progressive MS (PPMS)
• •Any history of treatment with recombinant humanized monoclonal antibodies
• •Has received treatment with immunosuppressant medications or experimental agents within 3 months prior to the Baseline
• •A history of opportunistic infection or the presence of any active infection within 3 months prior to Baseline
• •Any history of congestive heart failure or currently has a pacemaker
• •Has a known or suspected hypersensitivity to sulfonamides or any of the components of the investigational drug
• •Has any medical history or psychiatric condition that would impact outcome or study participation
• •Has other clinically significant abnormality on physical, neurological, laboratory, or ECG examination as listed in the protocol during the Screening Phase